ENTA logo

ENANTA PHARMACEUTICALS INC

ENTANASDAQ
🏆 #3195 by market capEarnings Nov 16US Equity
——
Quote unavailable
🔔
Track ENTA
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$329M
Small Cap
📈Revenue Growth (YoY)
0.7%
Slowing
📊Gross Margin
—
💵FCF Margin
26.6%
Strong
⚖️P/S Ratio
5.4x
Fair
Otter Score
—
Insufficient data
No chart data available for ENTA.

Trading Snapshot

Day Range
—
52-Week Range
$10.22 – $17.15
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
29.1M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
$65M
Last Q Revenue
$14M
P/E Ratio
—
P/S Ratio
5.4x
EPS (TTM)
$-2.41
Dividend Yield
—
Dilution (1yr)
+35.4%
ENTA logo

ENANTA PHARMACEUTICALS INC

ENTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$65M▼ −3.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.0%▼ −7.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$85M▼ −29.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$32M▼ −66.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
28.7M▲ +35.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$156M▼ −$19M YoY
StockOtter · stockotter.space

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.